|Print Page Close Window|
BeiGene is a commercial-stage biopharmaceutical company rooted in China that is dedicated to becoming a global leader in the discovery, development and commercialization of innovative, molecularly targeted and immuno-oncology drugs for the treatment of cancer.
We have three internally-developed late-stage clinical drug candidates:
BGNE (American Depositary Shares)
05/21/18 4:00 p.m. ET
Currency is USD
23 May 2018 10:30 a.m. ET
Sign up to receive e-mail alerts
© 2016 BeiGene. All Rights Reserved.